In summary, our findings indicate that setmelanotide treatment effectively activates PVN MC4R by upregulating the CaMKK2/AMPK pathways, thereby inhibit hyperphagia and reverse obesity in HO rats. Here, CAMKK2 is linked to obesity disorder.